As
Posted:
June 17, 2026
Location:
Palo Alto, CA, United States
Job Description
Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company with locations in Denmark, Europe, and the United States. Today, we're advancing programs in Endocrinology Rare Disease and Oncology.
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where skilled, adaptable, and highly resourceful professionals can truly make their mark. We offer a dynamic workplace for employees to grow and develop their skills.
The Senior Clinical Scientist is involved in the design, monitoring, and data analysis of the Company’s late-phase clinical trials studying growth hormone, parathyroid hormone, and/or C-type natriuretic peptide thera...
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where skilled, adaptable, and highly resourceful professionals can truly make their mark. We offer a dynamic workplace for employees to grow and develop their skills.
The Senior Clinical Scientist is involved in the design, monitoring, and data analysis of the Company’s late-phase clinical trials studying growth hormone, parathyroid hormone, and/or C-type natriuretic peptide thera...
Apply for this Job
Submit your application for the Clinical Scientist - Job ID: 1845, 1915, 1916 position at Ascendis Pharma.
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Palo Alto, United States
Posted:
June 17, 2026
Deadline:
June 21, 2026